Mass manufacturing of COVID-19 vaccines is complex and takes time. Up to 70% of manufacturing time is spent on testing and quality controls, ensuring doses are safe and effective. The European Commission is working with industry to step up manufacturing capacity, and fast and large-scale distribution of doses to Europeans.
EU Exit and Post Transition guidance webinar presented by MHRA Device Regulatory Group.
Dr June Raine, Chief Executive for the Medicines and Healthcare products Regulatory Agency (MHRA), provides answers about how COVID-19 vaccines are approved in the UK
Interface between medicinal product and medical devices development- Update on EMA implementation of new medical devices legislation.
Copyright © 2022 Medical Device Advice, Inc. - All Rights Reserved.
This website uses cookies. By continuing to use this site, you accept our use of cookies.